Home Analyst Price Target

Analyst Price Target

Curaleaf: Analysts Are Hopeful ahead of Q3 Release

Curaleaf is set to report its third-quarter earnings results on November 19. It's fallen more than 6% since it announced its earnings date.

MedMen: Analysts’ Latest Ratings and Price Target

The cannabis sector is currently abuzz with earnings. MedMen Enterprises (MMEN) (MMNFF) is one of the first few to report.

Is Cronos Stock a Buy in October?

On October 28, Cronos (CRON) closed at 11.39 Canadian dollars on the Toronto Stock Exchange. This implies a 3.96% decline since the beginning of October.

Cronos Group: Analysts’ Target Prices and Ratings

Cronos Group (CRON) is already down by 15.59% so far in 2019. Although the company hasn’t escaped the gloom that has surrounded the cannabis...

Aphria: Analysts’ Ratings and Price Target

On October 15, Aphria (APHA) reported its earnings for the first quarter of fiscal 2020. For the quarter, the company’s revenue came in lower...

Tilray Stock: Analysts’ Price Targets and Ratings

Recently, along with many of its cannabis peers, Tilray (TLRY) stock has seen a fall in its target price. Let's take a closer look.

Cannabis Sector: Piper Jaffray Favors Canopy and Cronos

So far, cannabis stocks have struggled this year. Many of the stocks didn’t impress investors with their earnings results. Analysts downgraded and cut many...

Canopy Growth: Analysts’ Target Prices and Ratings

Canopy Growth (CGC) (WEED) is already down by 24.26% in 2019 YTD (year-to-date). Macro-economic and political uncertainty across the global market have already taken...

Aphria: Analysts’ Target Price and Ratings after Earnings

On Tuesday, Aphria (APHA) reported impressive results for the first quarter of fiscal 2020 on Tuesday. The stock has risen 9.6% since its earnings....